Gankyrin/PSMD10 蛋白, Human

Gankyrin/PSMD10 protein is a critical chaperone in 26S proteasome assembly, contributing to PA700/19S regulatory complex (RC) formation. In base subcomplex assembly, it engages with PSMD10, PSMC4, PSMC5, and PAAF1, likely connecting with PSMD5, PSMC2, PSMC1, and PSMD2. Independently, Gankyrin regulates EGF-induced AKT activation by inhibiting the RHOA/ROCK/PTEN pathway. It plays a key role in RAS-induced tumorigenesis, acting as a proto-oncoprotein by negatively regulating RB1 and p53/TP53. Gankyrin overexpression leads to RB1 phosphorylation and degradation, while also competing with CDKN2A for CDK4 binding. Additionally, Gankyrin facilitates MDM2-p53/TP53 binding and promotes p53/TP53 ubiquitination by MDM2, influencing the TP53:MDM2 complex's targeting to the 26S proteasome. Involved in p53-independent apoptosis, Gankyrin regulates NF-kappa-B by retaining RELA in the cytoplasm and facilitating its XPO1/CRM1-mediated nuclear export. Gankyrin/PSMD10 Protein, Human is the recombinant human-derived Gankyrin/PSMD10 protein, expressed by E. coli, with tag free. The total length of Gankyrin/PSMD10 Protein, Human is 226 a.a., with molecular weight of ~26.0 kDa.

Gankyrin/PSMD10 蛋白在 26S 蛋白酶体组装过程中充当关键伴侣，特别有助于 PA700/19S 调节复合物 (RC) 的形成。在组装基础子复合体的初始步骤中，它参与具有 PSMD10、PSMC4、PSMC5 和 PAAF1 的中间模块，该模块可能与包含 PSMD5、PSMC2、PSMC1 和 PSMD2 的模块相关联。Gankyrin 独立于蛋白酶体，通过抑制 RHOA/ROCK/PTEN 通路来调节 EGF 诱导的 AKT 激活，从而延长 AKT 激活时间。此外，它在 RAS 诱导的肿瘤发生中发挥着关键作用，通过肿瘤抑制因子 RB1 和 p53/TP53 的负调控发挥原癌蛋白的作用。Gankyrin 过度表达导致 RB1 磷酸化和蛋白酶体降解，同时还通过与 CDKN2A 竞争与 CDK4 的结合来调节 CDK4 介导的 RB1 磷酸化。此外，Gankyrin 促进 MDM2 与 p53/TP53 的结合，并促进 MDM2 对 p53/TP53 的单泛素化和多泛素化，表明其在将 TP53:MDM2 复合物靶向 26S 蛋白酶体中发挥作用。它参与 p53 独立的细胞凋亡，并通过将 NF-kappa-B 保留在细胞质中、与 NF-kappa-B 成分 RELA 结合并促进其 XPO1/CRM1 介导的核输出来调节 NF-kappa-B。

Human

E. coli

Tag Free

O75832 (M1-G226)

5716  [NCBI]

MEGCVSNLMVCNLAYSGKLEELKESILADKSLATRTDQDSRTALHWACSAGHTEIVEFLLQLGVPVNDKDDAGWSPLHIAASAGRDEIVKALLGKGAQVNAVNQNGCTPLHYAASKNRHEIAVMLLEGGANPDAKDHYEATAMHRAAAKGNLKMIHILLYYKASTNIQDTEGNTPLHLACDEERVEEAKLLVSQGASIYIENKEEKTPLQVAKGGLGLILKRMVEG

Approximately 26.0 kDa

Greater than 95% as determined by reducing SDS-PAGE.

<1 EU/μg, determined by LAL method.